Find, compare & contact
Fluorodopa (18F)
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Fluorodopa (18F) API 92812-82-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Fluorodopa (18F). You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Fluorodopa (18F)
- Synonyms:
- 6-Fluoro-(18F)-L-3,4-Dihydroxyphenylalanine , Fluorodopa F-18 , L-3,4-Dihydroxy-6-[18F]Fluorophenylalanine
- Cas Number:
- 92812-82-3
- DrugBank number:
- DB13848
- Unique Ingredient Identifier:
- 2C598205QX
General Description:
Fluorodopa (18F), identified by CAS number 92812-82-3, is a notable compound with significant therapeutic applications. Fluorodopa F 18 is a fluorinated analog of used as a diagnostic agent for positron emission tomography (PET) in the evaluation of Parkinsonian syndromes. Fluorodopa F 18 PET is used adjunctly with other diagnostic investigations and serves primarily to visualize dopaminergic nerve terminals in the striatum.
Indications:
This drug is primarily indicated for: Fluorodopa F 18 is indicated for use with positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Fluorodopa (18F) undergoes metabolic processing primarily in: Fluorodopa F 18 is decarboxylated by aromatic amino acid decarboxylase (AADC) in the striatum to fluorodopamine F 18. Fluorodopamine F 18 is then further metabolized by monoamine oxidase (MAO) to yield 6-fluoro-3,4-dihydroxyphenylacetic acid, then subsequently by COMT to yield 6-fluorohomovanillic acid. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Half-life:
The half-life of Fluorodopa (18F) is an important consideration for its dosing schedule: The plasma half-life following intravenous administration is approximately 1-3 hours. This determines the duration of action and helps in formulating effective dosing regimens.
Route of Elimination:
The elimination of Fluorodopa (18F) from the body primarily occurs through: Approximately 80% of the administered radioactivity is eliminated in the urine. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Clearance:
The clearance rate of Fluorodopa (18F) is a critical factor in determining its safe and effective dosage: The agent is cleared from blood and tissue within 24 hours following administration. It reflects the efficiency with which the drug is removed from the systemic circulation.
Classification:
Fluorodopa (18F) belongs to the class of organic compounds known as tyrosine and derivatives. These are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom, classified under the direct parent group Tyrosine and derivatives. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Carboxylic acids and derivatives class, specifically within the Amino acids, peptides, and analogues subclass.
Categories:
Fluorodopa (18F) is categorized under the following therapeutic classes: Amines, Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Benzene Derivatives, Catecholamines, Catechols, Diagnostic Radiopharmaceuticals, Fluorine Radioisotopes, Phenols. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Fluorodopa (18F) is a type of Other substances
The pharmaceutical industry encompasses a diverse range of active pharmaceutical ingredients (APIs) that are used in the production of various medications. One category of APIs is known as other substances. This category includes substances that do not fall under the conventional classifications such as antibiotics, analgesics, or antihypertensives.
Other substances in pharmaceutical APIs consist of a broad array of chemical compounds with unique properties and applications. These substances play a crucial role in the formulation and development of specialized medications, catering to specific therapeutic needs. The category encompasses various substances like excipients, solvents, stabilizers, and pH adjusters.
Excipients are inert substances that aid in the manufacturing process and enhance the stability, bioavailability, and patient acceptability of pharmaceutical formulations. Solvents are used to dissolve other ingredients and facilitate their incorporation into the final product. Stabilizers ensure the integrity and shelf life of medications by preventing degradation or chemical changes. pH adjusters help maintain the desired pH level of a formulation, which can influence the drug's efficacy and stability.
Pharmaceutical manufacturers carefully select and incorporate specific other substances into their formulations, adhering to regulatory guidelines and quality standards. These substances undergo rigorous testing and evaluation to ensure their safety, efficacy, and compatibility with the desired pharmaceutical product. By employing other substances in API formulations, pharmaceutical companies can optimize drug delivery, improve patient compliance, and enhance therapeutic outcomes.
In summary, the other substances category of pharmaceutical APIs comprises a diverse range of chemicals, including excipients, solvents, stabilizers, and pH adjusters. These substances contribute to the formulation, stability, and performance of medications, enabling pharmaceutical manufacturers to develop specialized products that meet specific therapeutic requirements.
